lanvis 40 mg tabletki
aspen pharma trading ltd. - tioguaninum - tabletki - 40 mg
kalydeco
vertex pharmaceuticals (ireland) limited - iwakaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
xanderla 3,6 mg implant w ampułko-strzykawce
teva pharmaceuticals polska sp. z o.o. - goserelini acetas - implant w ampułko-strzykawce - 3,6 mg
orkambi
vertex pharmaceuticals (ireland) limited - kombinaci lumacaftor, ivacaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - tabletki orkambi są wskazane w leczeniu mukowiscydozy (cf) u pacjentów w wieku 6 lat i starszych, które są гомозиготами mutacji f508del w genie cftr . orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.
trozel 2,5 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - letrozolum - tabletki powlekane - 2,5 mg
rosufy 5 mg tabletki powlekane
centrient pharmaceuticals netherlands b.v. - rosuvastatinum calicum - tabletki powlekane - 5 mg
rosufy 10 mg tabletki powlekane
centrient pharmaceuticals netherlands b.v. - rosuvastatinum calicum - tabletki powlekane - 10 mg
rosufy 20 mg tabletki powlekane
centrient pharmaceuticals netherlands b.v. - rosuvastatinum calicum - tabletki powlekane - 20 mg
rosufy 40 mg tabletki powlekane
centrient pharmaceuticals netherlands b.v. - rosuvastatinum calicum - tabletki powlekane - 40 mg
abiraterone glenmark 250 mg tabletki
glenmark pharmaceuticals s.r.o. - abirateroni acetas - tabletki - 250 mg